The Future of Central Nervous System Therapy

There's still a pretty serious unmet need for central nervous system Waldenstrom's the so-called bing needle. I think that over time, we are going to see migration as anobrutinib. It's clearly not more effective than a bruteinib. But it does appear that the toxicity profile really is superior. Half of ASCOs, leukemia is on vinetoclax. And if it has activity in Waldenstroms, we really should understand better how to position it.